99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
Year: 2021
Type: article
Source: Journal of Thoracic Oncology
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, University of California, Irvine, Henry Ford Hospital, Virginia Cancer Specialists, South Texas Accelerated Research Therapeutics, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Sarah Cannon, Tennessee Oncology, Massachusetts General Hospital, UC San Diego Health System, Moores Cancer Center, Mary Crowley Cancer Research Center, University of Colorado Anschutz, Mirati Therapeutics (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Lance Armstrong Foundation, Armstrong Foundation, LUNGevity Foundation, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, International Association for the Study of Lung Cancer, American College of Radiology Imaging Network, Novocure, Mirati Therapeutics, Revolution Medicines, Puma Biotechnology, Eisai, Astellas Pharma, Genentech, EMD Serono, Chugai Pharmaceutical, Takeda Oncology, Ignyta, Loxo Oncology, Daiichi Sankyo Europe
OpenAlex ID: W3145860562